[1]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152-156,170.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):152-156,170.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
点击复制

131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第3期
页码:
152-156,170
栏目:
出版日期:
2014-05-25

文章信息/Info

Title:
A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma
作者:
李莉;  晋建华;  陆克义;  刘建中;  李思进;  武志芳
030001 太原, 山西医科大学第一医院核医学科
Author(s):
Li Li;  Jin Jianhua;  Lu Keyi;  Liu Jianzhong;  Li Sijin;  Wu Zhifang
Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
甲状腺肿瘤; 碘放射性同位素; Meta分析; 随机对照试验
Keywords:
Thyroid neoplasms; Iodine radioisotopes; Meta-analysis; Randomized controlled trials
DOI:
10.3760/cma.j.issn.1673-4114.2014.03.003
摘要:
目的 用meta分析方法评价不同剂量131I去除分化型甲状腺癌(DTC)术后残留甲状腺组织(简称清甲)的疗效。方法 检索Cochrane图书馆、MEDLINE、OVID、Embase、EBSCO、SpringerLink等数据库,初筛1980年1月至2013年8月有关高剂量(3700 MBq)与低剂量(1110 MBq)131I清甲治疗疗效的随机对照试验(RCT)文献。采用改良的Jadad量表对入选文献进行质量评价,用RveMan 5.1软件进行统计学分析。结果 按照纳入及排除标准,共入选12篇RCT文献,共2290例患者。其中,高剂量组1069例、低剂量组1221例。按各文献报道的DTC患者术后131I清甲治疗成功标准,高剂量组与低剂量组首次清甲成功率之间的差异无统计学意义(Z=1.80,P>0.05);低、高剂量组分别采用重组人促甲状腺激素法(311例vs.288例)与激素撤退法(314例vs.284例)两种131I治疗准备方法时,两种方法首次清甲成功率之间的差异也无统计学意义(Z=0.98和0.33,P>0.05)。采用SF-36量表法分析DTC患者术后首次清甲治疗期间患者生活质量,两剂量组间差异也无统计学意义(Z=0.37,P>0.05),但高剂量组不良反应发生率明显高于低剂量组(Z=5.15,P<0.01),且所需隔离时间短。结论 131I高剂量组与低剂量组以及两种不同准备方法的清甲治疗疗效基本一致,两剂量组治疗期间患者生存质量也无明显差别,但低剂量组较高剂量组的严重不良反应的发生率小。研究提示,对低风险DTC患者使用低剂量131I治疗可获得与高剂量131I治疗一致的清甲效果,同时可减少不良反应的发生。
Abstract:
Objective To assess the effects of two different doses of 131I (3700 MBq vs.1110 MBq) for ablation of thyroid remnant in patients with differentiated thyroid carcinoma (DTC) by using meta analysis.Methods Collected the eligible trials by searching the Cochrane Library,MEDLINE,OVID,EMBASE,EBSCO and SpringerLink from January 1980 to August 2013.All relevant studies were screened according to inclusion and exclusion criteria.A modified Jadad scale was used for quality evaluation of se-lected literatures.RveMan 5.1 software was used for statistical analysis.Results Twelve randomized con-trolled trails involving 2290 patients were included in accordance with the inclusion and exclusion criteria.According to the criteria of successful thyroid remnant ablation reported in each literature,no statistical difference was noted in the rate of successful remnant ablation between low-and high-dose 131I group (Z=1.80,P>0.05).Both the low-or high-dose of 131I ablation showed no significant difference in the rate of successful remnant ablation between the two methods (recombinant human thyrotropin vs.steroid with-drawal) of preparing therapy (Z=0.98 and 0.33,P>0.05).Also,no significant differences existed in qual-ity-of-life scores on the SF-36 between different 131I-dose groups (Z=0.37,P>0.05).The low-dose group showed lower incidence of adverse events (Z=5.15,P<0.01) and shorter hospital isolation time than that in high-dose 131I group.Conclusions Two different doses of 131I treatment and two different preparation methods have similar efficacy in ablation of residual thyroid tissue in patients with low risk DTC,but the incidence of adverse effects in low-dose 131I group is less.

参考文献/References:

[1] Sawka AM,Thephamongkhol K,Brouwers M,et al.Clinical review 170:a systematic review and meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer[J].J Clin Endocrinol Metab,2004,89(8):3668-3676.
[2] Creutzig H.High or low dose radioiodine ablation of thyroid rem-nants?[J].Eur J Nucl Med,1987,12(10):500-502.
[3] Johansen K,Woodhouse NJ,Odugbesan O.Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residu-al thyroid tissue in patients with differentiated thyroid cancer[J].J Nucl Med,1991,32(2):252-254.
[4] Bal C,Padhy AK,Jana S,et al.Prospective randomized clinical tri-al to evaluate the optimal dose of 131I for remnant ablation in pa-tients with differentiated thyroid carcinoma[J].Cancer,1996,77(12):2574-2580.
[5] M?enp?? HO,Heikkonen J,Vaalavirta L,et al.Low vs.high ra-dioiodine activity to ablate the thyroid after thyroidectomy for can-cer:a randomized study[J/OL].PLoS One,2008,3(4):e1885[2014-03-01].http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001885.
[6] Kukulska A,Krajewska J,Gawkowska-Suwińska M,et al.Radioio-dine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC):prospective comparison of long-term outcomes of treatment with 30,60 and 100 mCi[J].Thyroid Res,2010,3(1):9.
[7] Fallahi B,Beiki D,Takavar A,et al.Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma:a large randomized clinical trial[J].Nucl Med Commun,2012,33(3):275-282.
[8] Schlumberger M,Catargi B,Borget I,et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med,2012,366(18):1663-1673.
[9] Mallick U,Harmer C,Yap B,et al.Ablation with low-dose radioio-dine and thyrotropin alfa in thyroid cancer[J].N Engl J Med,2012,366(18):1674-1685.
[10] Caglar M,Bozkurt FM,Akca CK,et al.Comparison of 800 and 3700MBq iodine-131 for the postoperative ablation of thyroid rem-nant in patients with low-risk differentiated thyroid cancer[J].Nucl Med Commun,2012,33(3):268-274.
[11] Pacini F,Molinaro E,Castagna MG,et al.Ablation of thyroid residues with 30 mCi 131I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone with-drawal[J].J Clin Endocrinol Metab,2002,87(9):4063-4068.
[12] Barbaro D,Boni G,Meucci G,et al.Radioiodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer.effectiveness for postsurgical remnants ablation and possi-ble role of iodine content in L-thyroxine in the outcome of ablation[J].J Clin Endocrinol Metab,2003,88(9):4110-4115.
[13] Pacini F,Ladenson PW,Schlumberger M,et al.Radioiodine abla-tion of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma:results of an inter-national,randomized,controlled study[J].J Clin Endocrinol Metab,2006,91(3):926-932.
[14] Verkooijen RB,Verburg FA,van Isselt JW,et al.The success rate of I-131 ablation in differentiated thyroid cancer:comparison of uptake-related and fixed-dose strategies[J].Eur J Endocrinol,2008,159(3):301-307.
[15] Brown AP,Chen J,Hitchcock YJ,et al.The risk of second primary malignancies up to three decades after the treatment of differentiat-ed thyroid cancer[J].J Clin Endocrinol Metab,2008,93(2):504-515.
[16] Rosário PW,Borges MA,Purisch S.Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity[J].J Nucl Med,2008,49(11):1776-1782.
[17] Esfahani AF,Fallahi B,Olamaie R,et al.Semi-quantitative assess-ment of salivary gland function in patients with differentiated thy-roid carcinoma after radioiodine-131 treatment[J].Hell J Nucl Med,2004,7(3):206-209.
[18] Borget I,Remy H,Chevalier J,et al.Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients:comparison between preparation with thyroid hormone withdrawal and thyrogen[J].Eur J Nucl Med Mol Imaging,2008,35(8):1457-1463.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[15]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
　Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[16]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
　Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[17]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
　Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[18]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
　HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[19]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
　YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
[20]董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]
　DONG Feng,ZHOU Yin-bao.Influencing factors of radioiodine ablation of posts-urgical thyroid remnants in differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]

备注/Memo

备注/Memo:
收稿日期:2014-03-01。
基金项目:山西省卫生厅科技攻关计划项目(200702)
通讯作者:晋建华,Email:jjh1225@126.com
更新日期/Last Update: 1900-01-01